Tuesday, 13 October 202610:43 am ISTIndia edition

सच, सीधे आप तक

Book ad space

Just in

Health

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension Study

Image: Business Medical Dialogues. Rights remain with the publisher.

Oral denifanstat, a once-daily fatty acid synthase (FASN) inhibitor under development for moderate to severe acne vulgaris, demonstrated sustained efficacy through 52 weeks in a Phase 3 open-label...

Read the full report on Business Medical Dialogues

Story file

Section
Health
First reported by
Business Medical Dialogues
Reporter
dr. kamal kant kohli
Published
Monday, 12 October 2026, 9:15 pm IST
Coverage
One outlet so far

How this page works. The Headline Update lists this report from Business Medical Dialogues with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

Related stories

More Health news

See all